Table 2.
Results from study visits over 1 month for the lorcaserin (n = 24) and placebo (n = 24) groups using intent-to-treat methods
| Anthropometry | Placebo (mean ± SE) |
Lorcaserin (mean ± SE) |
F† | P† | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Week 0 | Week 1 | Week 2 | Week 4 | Week 0 | Week 1 | Week 2 | Week 4 | |||
| BMI (kg/m2) | 34.33 ± 1.11 | 32.43 ± 1.50 | 34.16 ± 1.09 | 34.23 ± 1.11 | 39.42 ± 1.11 | 39.26 ± 1.50 | 39.06 ± 1.09 | 38.84 ± 1.11 | 12.603 | 0.001* |
| WC iliac (cm) | 112.18 ± 2.72 | 113.41 ± 2.62 | 112.45 ± 2.57 | 113.58 ± 2.71 | 123.20 ± 2.66 | 122.98 ± 2.56 | 121.52 ± 2.51 | 123.09 ± 2.65 | 7.249 | 0.010* |
| WC umbilical (cm) | 113.33 ± 2.71 | 113.55 ± 2.72 | 114.62 ± 2.65 | 115.23 ± 2.48 | 122.86 ± 2.52 | 123.59 ± 2.53 | 122.05 ± 2.46 | 123.10 ± 2.30 | 6.201 | 0.017* |
| Hip (cm) | 118.44 ± 2.88 | 118.32 ± 2.75 | 116.99 ± 2.81 | 118.80 ± 2.74 | 126.04 ± 2.81 | 125.17 ± 2.68 | 125.11 ± 2.75 | 125.54 ± 2.68 | 3.617 | 0.065 |
| SBP (mmHg) | 131.00 ± 2.93 | 128.91 ± 2.77 | 133.83 ± 2.98 | 127.57 ± 2.71 | 123.50 ± 2.87 | 119.88 ± 2.71 | 123.21 ± 2.92 | 121.17 ± 2.65 | 6.786 | 0.012* |
| DBP (mmHg) | 78.74 ± 2.21 | 77.09 ± 2.24 | 77.22 ± 2.31 | 77.26 ± 2.29 | 74.13 ± 2.16 | 72.72 ± 2.19 | 75.42 ± 2.19 | 73.63 ± 2.24 | 1.974 | 0.167 |
| Mean BP (mmHg) | 104.87 ± 2.27 | 103.00 ± 2.20 | 105.52 ± 2.42 | 102.41 ± 2.31 | 98.91 ± 2.22 | 96.15 ± 2.15 | 99.31 ± 2.37 | 97.40 ± 2.26 | 5.067 | 0.029* |
BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure; WC, waist circumference.
†F and P values are from repeated-measures ANOVA over time.
*Indicates statistical significance (P < 0.05).